Difference between revisions of "Romiplostim (Nplate)"
m |
m |
||
| Line 10: | Line 10: | ||
*[http://chemocare.com/bio/romiplostim.asp Romiplostim (Nplate) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/romiplostim.asp Romiplostim (Nplate) patient drug information (Chemocare)]</ref> | *[http://chemocare.com/bio/romiplostim.asp Romiplostim (Nplate) patient drug information (Chemocare)]<ref>[http://chemocare.com/bio/romiplostim.asp Romiplostim (Nplate) patient drug information (Chemocare)]</ref> | ||
*[http://www.uptodate.com/contents/romiplostim-patient-drug-information Romiplostim (Nplate) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/romiplostim-patient-drug-information Romiplostim (Nplate) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/romiplostim-patient-drug-information Romiplostim (Nplate) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/romiplostim-patient-drug-information Romiplostim (Nplate) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | * 8/22/2008: Initial FDA approval | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drug index]] |
[[Category:Hematopoietic growth factors]] | [[Category:Hematopoietic growth factors]] | ||
[[Category:Megakaryocyte growth factors]] | [[Category:Megakaryocyte growth factors]] | ||
| + | [[Category:Hematology medications]] | ||
[[Category:Immune thrombocytopenic purpura (ITP) medications]] | [[Category:Immune thrombocytopenic purpura (ITP) medications]] | ||
| + | |||
| + | [[Category:Drugs FDA approved in 2008]] | ||
Revision as of 03:01, 3 November 2014
General information
Class/mechanism: Thrombopoietin (TPO/cMpl) receptor agonist. Romiplostim is an Fc-peptide fusion protein (peptibody) that interacts with the TPO receptor to trigger downstream signal cascades that ultimately stimulate platelet production by promoting proliferation and differentiation of megakaryocytes from bone marrow progenitor cells.[1][2]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Romiplostim (Nplate) package insert PDF pages 11-14[1]
- Romiplostim (Nplate) patient drug information (Chemocare)[3]
- Romiplostim (Nplate) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 8/22/2008: Initial FDA approval